Lambeck AJ - Search Results

1

Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells.

Schreibelt G, Benitez-Ribas D, Schuurhuis D, Lambeck AJ, van Hout-Kuijer M, Schaft N, Punt CJ, Figdor CG, Adema GJ, de Vries IJ. Schreibelt G, et al. Among authors: lambeck aj. Blood. 2010 Jul 29;116(4):564-74. doi: 10.1182/blood-2009-11-251884. Epub 2010 Apr 27. Blood. 2010. PMID: 20424184 Free article.

2

Human plasmacytoid dendritic cells phagocytose, process, and present exogenous particulate antigen.

Tel J, Lambeck AJ, Cruz LJ, Tacken PJ, de Vries IJ, Figdor CG. Tel J, et al. Among authors: lambeck aj. J Immunol. 2010 Apr 15;184(8):4276-83. doi: 10.4049/jimmunol.0903286. Epub 2010 Mar 19. J Immunol. 2010. PMID: 20304825

3

Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.

Lesterhuis WJ, de Vries IJ, Schreibelt G, Lambeck AJ, Aarntzen EH, Jacobs JF, Scharenborg NM, van de Rakt MW, de Boer AJ, Croockewit S, van Rossum MM, Mus R, Oyen WJ, Boerman OC, Lucas S, Adema GJ, Punt CJ, Figdor CG. Lesterhuis WJ, et al. Among authors: lambeck aj. Clin Cancer Res. 2011 Sep 1;17(17):5725-35. doi: 10.1158/1078-0432.CCR-11-1261. Epub 2011 Jul 19. Clin Cancer Res. 2011. PMID: 21771874 Free article.

4

Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity.

Tacken PJ, Zeelenberg IS, Cruz LJ, van Hout-Kuijer MA, van de Glind G, Fokkink RG, Lambeck AJ, Figdor CG. Tacken PJ, et al. Among authors: lambeck aj. Blood. 2011 Dec 22;118(26):6836-44. doi: 10.1182/blood-2011-07-367615. Epub 2011 Oct 3. Blood. 2011. PMID: 21967977 Free article.

5

Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell subsets.

Tel J, Schreibelt G, Sittig SP, Mathan TS, Buschow SI, Cruz LJ, Lambeck AJ, Figdor CG, de Vries IJ. Tel J, et al. Among authors: lambeck aj. Blood. 2013 Jan 17;121(3):459-67. doi: 10.1182/blood-2012-06-435644. Epub 2012 Dec 4. Blood. 2013. PMID: 23212525 Free article.

6

Robust COVID-19 vaccination response after allogeneic stem cell transplantation using post transplantation cyclophosphamide conditioning.

Morsink LM, van Doesum J, Choi G, Hazenberg CLE, Biswana A, Meppelink F, Bungener LB, Lambeck AJA, Huls G. Morsink LM, et al. Among authors: lambeck aja. Blood Cancer J. 2022 Jan 12;12(1):6. doi: 10.1038/s41408-021-00605-1. Blood Cancer J. 2022. PMID: 35022420 Free PMC article. No abstract available.

7

Low-affinity TCR engagement drives IL-2-dependent post-thymic maintenance of naive CD4+ T cells in aged humans.

van der Geest KS, Abdulahad WH, Teteloshvili N, Tete SM, Peters JH, Horst G, Lorencetti PG, Bos NA, Lambeck A, Roozendaal C, Kroesen BJ, Koenen HJ, Joosten I, Brouwer E, Boots AM. van der Geest KS, et al. Aging Cell. 2015 Oct;14(5):744-53. doi: 10.1111/acel.12353. Epub 2015 May 25. Aging Cell. 2015. PMID: 26010129 Free PMC article.

8

Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial.

Leffers N, Lambeck AJ, Gooden MJ, Hoogeboom BN, Wolf R, Hamming IE, Hepkema BG, Willemse PH, Molmans BH, Hollema H, Drijfhout JW, Sluiter WJ, Valentijn AR, Fathers LM, Oostendorp J, van der Zee AG, Melief CJ, van der Burg SH, Daemen T, Nijman HW. Leffers N, et al. Among authors: lambeck aj. Int J Cancer. 2009 Nov 1;125(9):2104-13. doi: 10.1002/ijc.24597. Int J Cancer. 2009. PMID: 19621448 Clinical Trial.

9

Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7.

Lambeck AJ, Crijns AP, Leffers N, Sluiter WJ, ten Hoor KA, Braid M, van der Zee AG, Daemen T, Nijman HW, Kast WM. Lambeck AJ, et al. Clin Cancer Res. 2007 Apr 15;13(8):2385-91. doi: 10.1158/1078-0432.CCR-06-1828. Clin Cancer Res. 2007. PMID: 17438097

10

P53-specific T cell responses in patients with malignant and benign ovarian tumors: implications for p53 based immunotherapy.

Lambeck A, Leffers N, Hoogeboom BN, Sluiter W, Hamming I, Klip H, ten Hoor K, Esajas M, van Oven M, Drijfhout JW, Platteel I, Offringa R, Hollema H, Melief K, van der Burg S, van der Zee A, Daemen T, Nijman H. Lambeck A, et al. Int J Cancer. 2007 Aug 1;121(3):606-14. doi: 10.1002/ijc.22710. Int J Cancer. 2007. PMID: 17415711

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

43 results

Search Page

Filters